The Dow Jones Industrial Average (DJINDICES: ^DJI ) is following markets in Asia and Europe lower today. As of 1:20 p.m. EDT the Dow is down 58 points, or 0.39%, to 15,064. The S&P 500 (SNPINDEX: ^GSPC ) is down 0.38% to 1,620.
There were no U.S. economic releases today. The Dow opened 100 points higher before falling nearly 200 points to where it sits now. And it looks like volatility is back: The VIX (VOLATILITYINDICES: ^VIX ) is up 4.4%.
So what does this mean for long-term investors? Well, the past two days' drops bring us down to a level not seen since...last Thursday. Yawn. Remember not to let yourself get caught up in the day-to-day market movements. Focus on companies' long term prospects and the news that affects them.
Today's Dow leader
Today's Dow leader is Hewlett-Packard (NYSE: HPQ ) , up 3.6%. HP recently signed a deal with Google that will allow the PC maker to sell PCs preprogrammed with Google software. The main reason the stock is up today, however, appears to be CEO Meg Whitman's CNBC appearance this morning. She said that revenue growth was possible for the company this year despite the broad decline of PC sales, which plummeted 14% in the first quarter of this year -- their biggest drop ever. She also discussed her turnaround of the company and how she believes it is on track.
10 Best China Stocks To Buy Right Now: Uroplasty Inc (UPI)
Uroplasty, Inc., incorporated in January 1992, is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions. The Company�� primary focus is on two products: the Urgent PC Neuromodulation system and Macroplastique Implants. The Urgent PC system is a United States Food and Drug Administration (FDA)-approved minimally invasive, office-based neuromodulation therapy for the treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence; and Macroplastique Implants a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency (ISD). Outside of the United States, the Company�� Urgent PC is also approved for treatment of fecal incontinence, and Macroplastique is also approved for treatment of male stress incontinence and vesicoureteral reflux.
Urgent PC Neuromodulation System
Using a small-gauge needle electrode inserted above the ankle, the Urgent PC System delivers electrical impulses to the tibial nerve that travel to the sacral nerve plexus, a control center for pelvic floor and bladder function. Components of the Urgent PC system include a hair-width needle electrode, a lead set, and an external, handheld, battery-powered stimulator. For each 30-minute, office-based therapy session, the physician or other qualified healthcare provider inserts the needle electrode in the patient�� lower leg and connects the electrode to the stimulator. Typically, a patient undergoes 12 consecutive weekly treatment sessions, with follow-up maintenance treatments as required to sustain the therapeutic effect. The Company has received regulatory clearances for sale of the Urgent PC system in the United States, Canada and Europe. It also has launched its second generation Urgent PC system.
Macroplastique
Macroplastique is designed to restore the patient�� urinary contine! nce immediately following treatment. Macroplastique is a soft-textured, permanent implant injected, under endoscopic visualization, around the urethra distal to the bladder neck. It is a composition of heat vulcanized, solid, soft, irregularly shaped polydimethylsiloxane (solid silicone elastomer) implants suspended in a biocompatible excretable carrier gel. Macroplastique does not degrade, is not absorbed into surrounding tissues and does not migrate from the implant site. The Company has sold Macroplastique for several urological indications in over 40 countries outside the United States.
Other Uroplasty Products
The Company markets outside of the United States minimally invasive products to address fecal incontinence. Its PTQ Implants offer minimally invasive, soft-textured permanent implant for treatment of fecal incontinence. The PTQ Implants are implanted circumferentially into the submucosa of the anal canal, creating a bulking and supportive effect similar to that of Macroplastique injection for the treatment of stress urinary incontinence. The PTQ is Conformite Europeenne (CE) marked and is sold outside the United States in various international markets. The Urgent PC is also CE marked and sold outside of the United States for the treatment of fecal incontinence. In addition to urological applications, the Company markets its tissue bulking material outside the United States for otolaryngology vocal cord rehabilitation applications under the trade name VOX Implants. In the Netherlands and the United Kingdom only, the Company distributes certain wound care products in accordance with a distributor agreement.
The Company competes with Pfizer Inc., Johnson and Johnson, Novartis, Allergan, GlaxoSmithKline, Carbon Medical Technologies, BioForm, Inc., Q-Med AB and Contura.
Advisors' Opinion:- [By Lisa Levin]
Uroplasty (NASDAQ: UPI) shares reached a new 52-week high of $5.22 after the company reported strong Q3 results.
Juniper Networks (NYSE: JNPR) shares gained 8.23% to touch a new 52-week high of $28.15 after the company reported better-than-expected fourth-quarter results. Barclays upgraded the stock from Equalweight to Overweight and lifted the price target from $29.00 to $34.00.
Top Long Term Stocks To Buy For 2014: Boston Scientific Corp (BSX)
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women�� Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In January 2011, it completed the acquisition of Sadra Medical, Inc. In March 2011, the Company completed the acquisition of Atritech, Inc. In February 2011, it announced the acquisitions of S.I. Therapies and ReVascular Therapeutics, Inc. In January 2011, the Company sold its Neurovascular business to Stryker Corporation. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System.
Interventional Cardiology
The Company offers coronary stent product. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease, which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart. The Company offers a two-drug platform strategy with its paclitaxel-eluting and everolimus-eluting stent system offerings, and it offers a range of stent sizes. The Company markets its next-generation internally-developed and self-manufactured PROMUS Element stent system in the United States, its Europe/Middle East/Africa (EMEA) region and certain Inter-Continental countries, including China and India. It markets the PROMUS everolimus-eluting stent system, supplied to the Company by Abbott Laboratories, in Japan. It also markets its TAXUS paclitaxel-eluting stent line, including its third-generation TAXUS Element paclitaxel-eluting stent system in the U.nited States, Japan, EMEA and certain Inter-Continental countries.
The Compa! ny markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA). The Company markets a family of intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. The iLab Ultrasound Imaging System continues as its flagship console and is compatible with its line of imaging catheters. The system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders. Sadra is developing a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. Atritech has developed a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The WATCHMAN Left Atrial Appendage Closure Technology, developed by Atritech, is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs, and is approved for use in CE Mark countries.
Cardiac Rhythm Management
The Company develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including Implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure, and implantable pacemaker systems used to manage slow or irregular heart rhyth! ms (brady! cardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. Its product offerings include its COGNIS cardiac resynchronization therapy defibrillator (CRT-D), its TELIGEN ICD systems and its ALTRUA family of pacemaker systems. During 2011, it began the United States launch of its next-generation line of defibrillators, INCEPTA, ENERGEN and PUNCTUA.
Endoscopy
The Company markets a range of products to diagnose, treat and ease a variety of digestive diseases, including those affecting the esophagus, stomach, liver, pancreas, duodenum, and colon. Common disease states include esophagitis, portal hypertension, peptic ulcers as well as esophageal, biliary, pancreatic and colonic cancer. The Company offers the Radial Jaw 4 Single-Use Biopsy Forceps, which are designed to enable collection of large high-quality tissue specimens without the need to use large channel therapeutic endoscopes. Its exclusive line of RX Biliary System devices are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. The Company also markets the Spyglass Direct Visualization System for direct imaging of the pancreatico-biliary system. The Spyglass System is a single-operator cholangioscopy device that offers clinicians a direct visualization of the pancreatico-biliary system and includes supporting devices for tissue acquisition, stone management and lithotripsy. Its products also include the WallFlex family of stents, in particular, the WallFlex Biliary line and WallFlex Esophageal line; and in 2011, the Company launched its Advanix Biliary Plastic Stent System and the Expect Endoscopic Ultrasound Aspiration Needle in the United States and certain international markets. Its Resolution Clip Device is an endoscopic mechanical clip designed to treat gastrointestinal bleeding.
T! he Company markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. Its product line includes pulmonary biopsy forceps, transbronchial aspiration needles, cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management. Asthmatx, Inc. designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma. The Alair Bronchial Thermoplasty System, developed by Asthmatx, has both CE Mark and Food and Drug Administration (FDA) approval and is the first device-based asthma treatment approved by the FDA.
Peripheral Interventions
The Company sells various products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. In 2010 and 2011, it launched several of its products internationally, including the EPIC self-expanding nitinol stent system in certain international markets, and the Carotid WALLSTENT stent system in Japan. The Company launched three new peripheral angioplasty balloons in 2011, including its next-generation Mustang percutaneous transluminal angioplasty (PTA) balloon, its Coyote balloon catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures and its Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company has commenced a limited ma! rket rele! ase of its OFFROAD re-entry catheter system in certain international markets, and in February 2012, it launched its TRUEPATH intraluminal CTO device in the United States.
The Company sells products designed to treat patients with non-vascular disease. Its non-vascular suite of products include biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continues to market its extensive line of Interventional Oncology product solutions, including the Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company�� FilterWire EZ Embolic Protection System is a filter designed to capture embolic material that may become dislodged during a procedure, which could otherwise travel into the microvasculature where it could cause a heart attack or stroke. It is commercially available in the United States, its EMEA region and certain Inter-Continental countries for multiple indications, including the treatment of disease in peripheral, coronary and carotid vessels. It is also available in the United States for the treatment of saphenous vein grafts and carotid artery stenting procedures.
Urology/Women�� Health
The Company�� Urology/Women�� Health division develops, manufactures and sells devices to treat various urological and gynecological disorders. The Company sells a variety of products designed to treat patients with urinary stone disease, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding. The Company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters.
The Company markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), and ! menorrhag! ia (excessive menstrual bleeding). It offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The Company markets its Genesys Hydro ThermAblator (HTA) system, a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. The Genesys HTA System features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface and is designed to improve operating performance.
Neuromodulation
The Company within its Neuromodulation business markets the Precision Spinal Cord Stimulation (SCS) system, used for the management of chronic pain. In 2011, the Company launched its Clik Anchor for its Precision Plus SCS System, a rechargeable SCS device for chronic pain management. During 2011, it received FDA approval for and launched the Infinion 16 Percutaneous Lead, a 16-contact percutaneous lead. The Company also markets the Linear 3-4 and Linear 3-6 Percutaneous Leads for use with its SCS systems, which are designed to provide physicians more treatment options for their chronic pain patients. Intelect Medical, Inc. is a development-stage company developing advanced visualization and programming for the Vercise system.
Electrophysiology
The Company within its Electrophysiology business develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Included in its product offerings are radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Its products include the Blazer and Blazer Prime line of temperature ablation catheters, designed to deliver enhanced performance, responsiveness, and durability. Its cooled ablation portfolio includes the closed-loop irrigated catheter on the market, the Chilli II cooled! ablation! catheter, and the newly launched Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design.
The Company competes with Abbott Laboratories, Medtronic, Inc., St. Jude Medical, Inc. and Johnson & Johnson.
Advisors' Opinion:- [By Brian Orelli]
Dragging down sales were medical devices, which saw sales drop 3% at constant currency. Much of the decline came from sales of its drug-eluting stent and related products, which fell 15% in the U.S. compared to the first quarter of 2012. U.S. sales are being dragged down by pricing pressure as it competes with Boston Scientific (NYSE: BSX ) and decreased usage by the doctors. Boston Scientific reported a similar experience with U.S. sales of drug-eluting stents down a whopping 33%.
- [By Dan Caplinger]
Boston Scientific (NYSE: BSX ) , up 23.4%
Medical-device maker Boston Scientific had two favorable pieces of news during the month. First, it announced data that supported the conclusion that its Watchman device did a better job of preventing conditions like strokes and cardiovascular death than the typical treatment, warfarin. Then about a week later, Boston Scientific revealed that it had found its first patient in its study of its WallFlex Biliary RX self-expanding metal stent. Despite facing big competition and the headwind of Obamacare's medical device excise tax, Boston Scientific's advances are good news for investors.
Top Long Term Stocks To Buy For 2014: Constellation Energy Partners LLC (CEP)
Constellation Energy Partners LLC (CEP) is engaged on the acquisition, development and production of onshore oils and natural gas properties in the United States. All of the Company's proved reserves are located in the Black Warrior Basin in Alabama, the Cherokee Basin in Kansas and Oklahoma, the Woodford Shale in the Arkoma Basin in Oklahoma and the Central Kansas Uplift in Kansas and Nebraska. The Company operates its oil and natural gases properties as one business segment: the exploration, development and production of oil and natural gas. As of December 31, 2011, the Company's total estimated proved reserves were approximately 201.3 billions of cubic feet equivalent (Bcfe), approximately 76% of which were classified as proved developed, and 97% of which are natural gas and 3% of which are oil. As of December 31, 2011, the Company was the operator of approximately 88% of the 2,785 net wells in which the Company owned an interest. In March 2013, it announced sale of its Robinson's Bend Field assets, located in Tuscaloosa County, Alabama.
Black Warrior Basin
The Black Warrior Basin is a coalbed methane basins in the country. The multi-seam vertical wells in the basin range from 500 to 3,700 feet deep, with coal seams averaging a total of 25 to 30 feet of net pay per well. As of December 31, 2011, the Company owned a 100% working interest (an approximate 75% average net revenue interest) in its wells in the Black Warrior Basin, where the Company had 507 producing natural gas wells. The Black Warrior Basin is located in western Tuscaloosa County and Pickens County, Alabama, and encompasses a surface area of approximately 109 square miles. The field has been developed on 80-acre spacing. As of December 31, 2011, the Company was developing its properties in the field on both 40- and 80-acre spacing. The field has seven compressor stations with 800-1,200 horsepower compressors, approximately 170 miles of gas gathering lines (wells to header) and approximately 25 miles of trans! portation lines (header to compressor). In addition, there are approximately 152 miles of water gathering pipes and 28 miles of water transportation pipes. As of December 31, 2011, the Company's estimated proved reserves in the Black Warrior Basin were approximately 84.9 billions of cubic feet equivalent, approximately 88% of which were classified as proved developed, and all of which are natural gas.
Cherokee Basin
The Cherokee Basin is located in the Mid-Continent region in southern Kansas, northern Oklahoma, and western Missouri. It covers approximately 26,500 square miles. The production is natural gas produced from coals and shales. There are multiple producing coal zones in the Cherokee Basin, including the Rowe, Riverton, Weir-Pitt, and Dawson zones. In addition, there are other productive shale zones, as well as conventional sandstone and limestone potential, which can add natural gas and oil production. As of December 31, 2011, the Company owned approximately 2,261 net producing wells in the Cherokee Basin. The Company operates in excess of 20 booster compressors and stations to gets its natural gas to sales points owned by ONEOK Gas Transportation, L.L.C., Scissortail Energy, LLC, Enogex Gas Gathering & Processing, LLC, Enogex Inc., and Southern Star Central Gas Pipeline, Inc. The Company operates a substantial portion of its production in the Cherokee Basin. The Company also own a 50% working interest in wells operated by Bullseye Operating, L.L.C. (Bullseye) and a 50% interest in Bullseye itself. Bullseye operates approximately 500 gross wells in Washington and Nowata Counties in Oklahoma and sells its production through the Cotton Valley producers cooperative, Cotton Valley Compression, L.L.C. The Company's gross working interest in its Cherokee Basin properties is approximately 80%, with its average gross working interest in its operated properties being approximately 100% and its average gross working interest in its non-operated Cherokee Basin properties being a! pproximat! ely 50%. As of December 31, 2011, the Company's estimated proved reserves in the Cherokee Basin were approximately 110.7 billions of cubic feet equivalent, approximately 66% of which were classified as proved developed, and 95% of which were natural gas and 5% of which were oil.
Woodford Shale
The Woodford Shale is located in the Arkoma Basin in southern Oklahoma. As of December 31, 2011, the Company owned 82 well bores, or approximately 9 net producing wells, located in Coal and Hughes counties. This area is gas-rich and is characterized by multiple productive zones. The production of natural gas in the Woodford Shale comes from shale rock that has been stimulated through fracturing jobs after a horizontal well has been drilled. As of December 31, 2011, the Company's 82 wells had an average gross working interest of 11.3% and an average net revenue interest of 9.1%. Approximately 90% of the wells are operated by affiliates of Devon Energy Corporation (Devon) and Newfield Exploration Mid-Continent, Inc. (Newfield), with the remaining wells operated by three additional companies. As of December 31, 2011, the Company's estimated proved reserves in the Woodford Shale were approximately 5.2 billions of cubic feet equivalent.
Central Kansas Uplift
The Central Kansas Uplift is an oil prone region located in Kansas and southern Nebraska. As of December 31, 2011, the Company had a gross acreage position of 4,345 acres, or approximately 1,050 net acres and the Company owned 39 gross wells, or approximately 8 net producing wells. Murfin Drilling Company, Inc., an oil producer in Kansas, operates all of the Company's wells in this region. During the year ended December 31, 2011, the average gross working interest in the wells is approximately 21% and the average net revenue interest is approximately 17%. As of December 31, 2011, the Company's proved reserves in the Central Kansas Uplift were approximately 0.5 billions of cubic feet equivalent, approximately 88%! of which! were classified as proved developed and all of which were oil.
Advisors' Opinion:- [By Rich Smith]
The bulk of these awards came in the form of a single multiple-award, task-order contract to be shared among several energy companies:
Constellation Energy Partners LLC's (NYSEMKT: CEP ) Constellation NewEnergy subsidiary Privately held ECC Renewables LLC Enel Green Power North America, a subsidiary of Italy's Enel SpA LTC Federal LLC Siemens' (NYSE: SI ) Government Technologies unitThese five firms are now authorized to bid for individual task orders under an umbrella contract for the procurement of renewable and alternative energy from facilities that are designed, financed, constructed, operated and maintained by private companies on private land under the jurisdiction of the Department of Defense. The ceiling value on this contract is $7 billion, thus accounting for 84% of the value of all Pentagon contracts awarded yesterday.
Top Long Term Stocks To Buy For 2014: (ARM)
ARM Holdings plc, together with its subsidiaries, engages in the design of microprocessors, physical IP, and related technology and software; and sale of development tools to enhance the performance of high-volume embedded applications. Its products include microprocessors cores, such as specific functions comprising video and graphics IP, fabric IP, embedded software, and configurable digital signal processing IP; physical IP components for the design and manufacture of integrated circuits, which comprise embedded memory, standard cell, and input/output components; software development tools that help software design engineers in the design and deployment of code, from applications running on open operating systems to low-level firmware. The company also offers support, maintenance, and training services, as well as design consulting services. ARM Holdings plc licenses and sells its technology and products to electronics companies, which in turn manufacture, market, and s ell microprocessors, application-specific integrated circuits, and application-specific standard processors to systems companies for incorporation into various end products, as well as licenses and sells development tools directly to systems companies and provides support services to licensees, systems companies, and other systems designers. It operates in Europe, the United States, and the Asia Pacific. The company was formerly known as Advanced RISC Machines Holdings Limited and changed its name to ARM Holdings plc in March 1998. ARM Holdings plc was founded in 1990 and is based in Cambridge, the United Kingdom.
Advisors' Opinion:- [By Sofia Horta e Costa]
ARM Holdings Plc (ARM) lost 2.6 percent, leading European technology companies lower before it publishes half-year results next week. IMI Plc (IMI) gained 2 percent as Citigroup Inc. listed the engineering company among its most preferred stocks.
- [By Tom Stoukas]
ARM Holdings Plc (ARM), whose chip designs power Apple Inc.�� iPhone and iPad, plunged 5.2 percent to 995 pence. Exane BNP Paribas downgraded the shares to neutral from outperform, saying that Intel Corp.�� new platform may enable it to outperform ARM�� designs.
- [By Sarah Jones]
European stocks jumped the most in eight months as ARM (ARM) Holdings Plc and Cie. Financiere Richemont SA reported results that topped estimates and speculation grew that the region�� central bank will cut interest rates.
Top Long Term Stocks To Buy For 2014: CommonWealth REIT (CWH)
CommonWealth REIT is a real estate investment trust launched and managed by Reit Management & Research LLC. The fund invests in the real estate markets of the United States. It seeks to invest in office buildings, industrial buildings, and leased industrial land. CommonWealth REIT was founded in 1986 and is domiciled in United States.
Advisors' Opinion:- [By Bill Stoller]
After a banner 2013, the overall market has had a challenging start to 2014. However, these four companies have been crushing it: Alexander Real Estate (NYSE: ARE ) , BioMed Realty Trust (NYSE: BMR ) , CommonWealth REIT (NYSE: CWH ) , and Sun Communities (NYSE: SUI ) early on in 2014 vs. the S&P 500. Their relative out-performance can also be seen when compared to the Vanguard REIT Index ETF (NYSEMKT: VNQ ) a good yardstick to measure sector performance.
- [By Canadian Value]
Real estate guru thinks that shareholders at CommonWealth REIT (CWH) have very little say in what is going on.
In this case there is an outside manager looking after assets they don't own.
- [By John Kell var popups = dojo.query(".socialByline .popC"); popups.forEach(func]
Corvex Management LP and Related Fund Management LLC called for an earlier special meeting to replace CommonWealth REIT's(CWH) entire board, with the activist investors criticizing the company’s former board for leaving without engaging in a transition process.
Top Long Term Stocks To Buy For 2014: Massive Dynamics Inc (MSSD)
Massive Dynamics, Inc., incorporated on March 15, 2011, is a development-stage company. The Company is providing services to communication tower operators. On August 20, 2012, Kylemore Corp. (Kylemore) approximately 90% of the Company. On April 16, 2013, the Company entered into an Asset Purchase Agreement with Real-View 3D (RV3D). With the Company's acquisition of the assets of RV3D, the Company is providing engineering and compliance to communications tower operators to three dimension (3D) imaging. RV3D is an image capture product company that has developed and is committed to design, patent, manufacture and market 3D imaging Z-axis capture products for the consumer computer peripherals market.
The Company has developed technology around an imaging technology known as structured light, which allows for the rapid capture and processing of the digital signal capture 3D images of objects or real time 3D video of a desired target. A structured light image is a calibrated grid of lines that is projected on the subject. These projected lines deviate as they fall over the subject. An image of these lines is captured. Real View 3D software can extract Z-axis data from these line deviations and a topographical map is created. To image a complete subject, the subject is rotated 360 degrees for the image and then another 360 degree rotation for capturing the structured light for the Z axis map information. The resulting Z axis map and the image are then fused into a 360 degree renderable image. This image can then be exported into many other formats for viewing. The Company's primary business will be to develop and market 3D scanning, capture, rendering, and printing products to four markets: consumer, commercial, industrial, and medical.
Advisors' Opinion:- [By Rich Smith]
The problem with that, of course, is that competition is beginning to emerge in machine selling, as small companies with names such as ExOne (NASDAQ: XONE ) and Massive Dynamics (NASDAQOTH: MSSD ) begin to horn in on the printer biz. Competition will probably arise even faster in the selling of printing composites, as Hewlett-Packard discovered to its detriment, when printer ink cartridge "refillers" began stealing away its lucrative ink business.
No comments:
Post a Comment